Details of the Drug Combinations

General Information of This Drug (ID: DM5FSJA)

• Drug Name: Glimepiride (DM5FSJA)
• Synonyms: Amarel; Amaryl; Endial; Glimepirid; Glimepirida; Glimepiridum; Glimepride; Glimer; Glymepirid; Roname; Solosa; Glimepirida [Spanish]; Glimepiridum [Latin]; Sandoz glimepiride; HOE 490; Amaryl (TN); Hoe-490; Novo-glimepiride; PMS-glimepiride; Ratio-glimepiride; Amaryl, Glista OD, Glimepiride; Glimepiride [USAN:BAN:INN]; Glimepiride (JAN/USP/INN); 1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea; 1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea; 3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; 3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro; 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide; 64598P

Indication

Diabetic complication; ICD 11: 5A2Y; Status: Approved [1]

• Therapeutic Class: Hypoglycemic Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Glimepiride + Idarubicin	DCLJUT8	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]

16 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Glimepiride + Metformin	DC312LB	Metformin	Type 2 Diabetes Mellitus	[3]
Glimepiride + Vildagliptin	DC87J1A	Vildagliptin	Diabetes Mellitus, Type 2	[4]
Glimepiride + Dapagliflozin	DCD2QOR	Dapagliflozin	Type 2 Diabetes Mellitus	[5]
Glimepiride + Rosiglitazone	DCNKMBL	Rosiglitazone	Diabetes	[6]
Glimepiride + Canagliflozin	DCZUJIB	Canagliflozin	Type2 Diabetes Mellitus	[7]
Liraglutide + Glimepiride	DCR8KQW	Liraglutide	Diabetes	[8]
Ranolazine + Glimepiride	DCQ6TIP	Ranolazine	Type 2 Diabetes Mellitus	[9]
Glimepiride + PF-04971729	DCRS04I	PF-04971729	Type 2 Diabetes Mellitus	[10]
Glimepiride + Sitagliptin	DC9T0X0	Sitagliptin	Type 2 Diabetes Mellitus	[11]
Glimepiride + PF-04971729	DCGTXL7	PF-04971729	Type 2 Diabetes Mellitus	[12]
Glimepiride + Atorvastatin	DCNMR1W	Atorvastatin	Type 2 Diabetes Mellitus	[13]
Glimepiride + TAK-875	DCHI8O8	TAK-875	Diabetes Mellitus, Type 2	[14]
MK-3102 + Glimepiride	DCH06VR	MK-3102	Type 2 Diabetes Mellitus	[15]
Glimepiride + Metformin	DCG2FK7	Metformin	Type 2 Diabetes Mellitus	[16]
Glimepiride + Dapagliflozin	DCNX2UH	Dapagliflozin	Type2 Diabetes	[17]
Glimepiride + Saxagliptin	DCX4F13	Saxagliptin	Type 2 Diabetes	[18]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6820).
• [2] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [3] ClinicalTrials.gov (NCT01340768) Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)
• [4] ClinicalTrials.gov (NCT00099944) Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes
• [5] ClinicalTrials.gov (NCT00842556) Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects
• [6] ClinicalTrials.gov (NCT00343980) Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes
• [7] ClinicalTrials.gov (NCT02956044) Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin
• [8] ClinicalTrials.gov (NCT01511692) Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes
• [9] ClinicalTrials.gov (NCT01494987) Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
• [10] ClinicalTrials.gov (NCT02036515) Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
• [11] ClinicalTrials.gov (NCT01177384) Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)
• [12] ClinicalTrials.gov (NCT02226003) Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017). U.S. National Institutes of Health.
• [13] ClinicalTrials.gov (NCT01477853) A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211). U.S. National Institutes of Health.
• [14] ClinicalTrials.gov (NCT01829477) Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes
• [15] ClinicalTrials.gov (NCT01704261) Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)
• [16] ClinicalTrials.gov (NCT01709305) A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
• [17] ClinicalTrials.gov (NCT02973477) Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
• [18] ClinicalTrials.gov (NCT02280486) Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin